Year: 2025

June 27, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMFDate   Shares   Voting rightsTheoretical* Exercisable**31 May 2025 43,203,225 48,990,941 48,941,337*This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation related to the calculation of the crossing of thresholds with regard to the number of voting rights. **For information purposes, this number excludes the shares which voting rights have been suspended. The information is also available in the « Regulated Information » section of the Ipsos website: https://www.ipsos.com/en/regulated-informations/en....

Siili Solutions Plc       Announcement  27.6.2025          Siili Solutions Plc: Share Repurchase 27.6.2025       In the Helsinki Stock Exchange         Trade date           27.6.2025  Bourse trade         Buy  Share                  SIILI  Amount             1 100 SharesAverage price/ share    6,3309 EURTotal cost            6 963,99 EUR          Siili Solutions Plc now holds a total of 19 949 sharesincluding the shares repurchased on 27.6.2025       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.     On behalf of Siili Solutions Plc         Nordea Bank Oyj         Sami Huttunen Ilari Isomäki       Further...

Lassila & Tikanoja plcStock Exchange Release 27 June 2025 at 5.50 pm Lassila & Tikanoja plc has refinanced its long-term debt financing Lassila & Tikanoja plc has today, 27 June 2025, entered into unsecured financing arrangements consisting of a EUR 35 million term loan and a EUR 15 million term loan and revolving credit facilities agreement with OP Corporate Bank Plc, as well as a EUR 40 million revolving credit facility agreement with Danske Bank A/S, Finland Branch. The financing arrangements are part of Lassila & Tikanoja plc’s refinancing of its long-term debt financing that was originally set to mature in 2026. The EUR 35 million term loan, the EUR 15 million term loan and revolving credit facilities, and the EUR 40 million revolving credit facility will mature in the second quarter of 2028, with a two-year...

STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia. On June 26 2025, the portfolio company Modus Therapeutics, listed on Nasdaq First North Growth Market, announced that the company is carrying out a fully secured rights issue of units that, upon full subscrption will provide the company with SEK 28.3 million before issue costs. The rights issue is subject to approval by an extraordinary general meeting held on July 29, 2025. The purpose of the rights issue is to provide capital for the continued clinical development of...

Nanjing, China, June 27, 2025 (GLOBE NEWSWIRE) — Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, issued the following statement in response to the market activity on June 26: The Company does not have any undisclosed material matters, nor is it aware of the specific reasons for the abnormal stock price fluctuations on June 26. However, we must caution investors and all other persons to rely solely on statements and filings with the U.S. Securities and Exchange Commission issued by the Company itself or its authorized representatives. The Company does not intend to make further statements regarding this matter. About Ostin Technology Group Co., Ltd. Founded in 2010, the Company is a supplier of display modules and polarizers in China. The Company...

FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Reverse Stock Split is intended to increase the market price per share of the Company’s Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the “NYSE American”) in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and into LNHC, Inc. and the related approximately $50 million in capital to be raised from a group of strategic investors led by Murchinson...